Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboprine SCHEMBL16805426 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL29552839 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL18503566 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4815729 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4599 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL18870819 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4600 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL25170535 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL31307032 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL8706995 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20070174931-A1 | Methods for controlling gibberellin levels | BROWN SHERRI M | 2007-07-26 | — | — | US | disclosed |
| US-7195917-B2 | Methods for controlling gibberellin levels | MONSANTO TECHNOLOGY LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-6723897-B2 | PROPAGATING TRANSGENIC PLANT; OBTAIN SAMPLE, INCUBATE WITH CHEMICAL INTERMEDIATES, PROPAGATE PLANT | MONSANTO TECHNOLOGY, LLC | 2004-04-20 | — | — | US | disclosed |
| US-20030233679-A1 | Methods for controlling gibberellin levels | MONSANTO TECHNOLOGY LLC. | 2003-12-18 | — | — | US | disclosed |
| US-20020053095-A1 | METHODS FOR CONTROLLING GIBBERELLIN LEVELS | ARNOLD WHITE & DURKEE | 2002-05-02 | — | — | US | disclosed |
| WO-2000009722-A2 | METHODS FOR CONTROLLING GIBBERELLIN LEVELS | MONSANTO COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5952545-A | Nucleic acid molecules encoding cytochrome P450-type proteins involved in the brassinosteroid synthesis in plants | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1999-09-14 | — | — | US | disclosed |
| US-5872104-A | BACTERICIDES AND RESISTANT BACTERIA WITH METHYLATION INHIBITORS | ORIDIGM CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0889963-A1 | NUCLEIC ACID MOLECULES ENCODING CYTOCHROME P450-TYPE PROTEINS INVOLVED IN THE BRASSINOSTEROID SYNTHESIS IN PLANTS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035986-A1 | NUCLEIC ACID MOLECULES ENCODING CYTOCHROME P450-TYPE PROTEINS INVOLVED IN THE BRASSINOSTEROID SYNTHESIS IN PLANTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070174931-A1 | Methods for controlling gibberellin levels | CYP21A2, CYP51A1, CYP17A1 | TP53 4694/4885LMNA 2308/4885ALOX15 211/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | TP53 1418/4885LMNA 625/4885ALOX15 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.